Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Study: large-scale MIGS study ➤ Partnership to advance early disease detection ➤ License agreement to move forward option for cataract surgery sedation ➤ Name change news ➤ ASCRS news and events
➤ FDA approves drop for mydriasis reversal ➤ Inventors of OCT honored with ‘American Nobel Prize’ ➤ Preservative-free latanoprost begins U.S. launch ➤ Enrollment complete in myopia treatment trial ➤ ASCRS news and events
➤ First AI foundation model in ophthalmology ➤ 24-month topline data from Phase 3 geographic atrophy therapy ➤ Positive data from Phase 1/2 trial for retinitis pigmentosa, Leber congenital amaurosis treatment ➤ FDA clearance granted for portable retinal imaging system ➤ ASCRS news and events
➤ FDA issues eight warning letters ➤ Positive Phase 2 safety update for investigational treatment of retinal diseases ➤ First-in-human titratable glaucoma therapy system ➤ Companies partner to develop biological dry eye treatment ➤ Geographic atrophy drug development discontinued ➤ ASCRS news and events
➤ Study: 1-year results with IOP-lowering implant ➤ Phase 2 study of investigational dry eye treatment nears enrollment target ➤ Study identifies antibody that could lead to retinitis pigmentosa treatment ➤ Gene therapy for inherited optic neuropathy approved for clinical trials ➤ ASCRS news and events
➤ FDA issues complete response letter for bevacizumab for retinal diseases ➤ First patient dosed in study evaluating X-linked retinoschisis ➤ Gene therapy study for Leber hereditary optic neuropathy begins dosing ➤ Update on rare retinal vasculitis events associated with GA treatment ➤ Eye drop recall grows ➤ ASCRS news and events
➤ FDA approves high-dose aflibercept ➤ Positive results in Phase 1 trial for cultivated autologous limbal epithelial cells ➤ Study: data from eye scans detect Parkinson’s disease years before clinical presentation ➤ Phase 2/3 study to evaluate persistent corneal epithelial defect treatment ➤ Phase 3 study offers results with aflibercept biosimilar ➤ ASCRS news and events
➤ First implantations for clinical trials for investigational IOLs ➤ Phase 2 clinical trial for wet AMD treatment completes enrollment ➤ Two-year results from trial showcase vision gains in wet AMD at extended aflibercept dosing intervals ➤ Acquisition update ➤ ASCRS news and events
➤ Positive Phase 3 results from trial investigating ocular pain, inflammation treatment ➤ Study evaluates use of sustained-release drug during Medicare pass-through program ➤ FDA approves treatment for geographic atrophy ➤ Dementia ‘much higher’ in patients with visual problems ➤ ASCRS news and events
➤ Update on safety review of geographic atrophy drug ➤ IND application accepted by FDA for wet AMD gene therapy ➤ Phase 2 trial planned for investigational neuropathic corneal pain treatment ➤ Interim Phase 2 data for sustained wet AMD treatment ➤ ASCRS news and events